20 Rodborough Road
Frenchs Forest, NSW 2086
Australia
61 2 9454 7200
https://www.syntaratx.com.au
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 27
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Gary Jonathan Phillips BPharm, MBA | CEO, MD & Director | 618,81k | N/A | 1961 |
Mr. David Morris McGarvey BA, CA, CPA | CFO & Company Secretary | 482,44k | N/A | 1956 |
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. | Head of Drug Discovery | 470,89k | N/A | 1964 |
Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin | Head of Medical & Regulatory Affairs - Alliance Management | 277,66k | N/A | 1972 |
Dr. Jana Baskar | Chief Medical Officer | 406,2k | N/A | N/A |
Mr. Cameron David Billingsley BA, LLB (Hons.) | General Counsel | N/A | N/A | 1977 |
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Syntara Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.